The FPR-1 protein is necessary for the recruitment of immune cells, namely neutrophils and inflammatory macrophages, to the lungs where they promote pulmonary fibrosis (PF), a mouse study shows. Depletion of FPR-1 or neutrophils prevented lung fibrosis and inflammation, supporting their potential as therapeutic targets in PF. The study…
News
The Pulmonary Fibrosis Foundation (PFF) and Celgene, a subsidiary of Bristol-Myers Squibb, are leading a collaboration with the long-term goal of streamlining the development of targeted treatment strategies for idiopathic pulmonary fibrosis (IPF), and the identification of disease biomarkers. In the majority of cases, the cause…
Pliant Therapeutics has raised $100 million in Series C financing that will support the clinical development of PLN-74809, a candidate therapy for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), a liver disease characterized by progressive inflammation and fibrosis of the bile ducts. The funding will…
In recognition of Rare Disease Day Feb. 29, Bionews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the #WhatMakesMeRare campaign was aimed at uplifting people with rare diseases by encouraging them to share their stories and perspectives. The…
A large-scale analysis of multiple genome-wide studies has identified three new gene variants — mutations in DNA sequences — associated with idiopathic pulmonary fibrosis, a study reported. Two of these genetic variants are not directly linked to fibrosis,…
Beginning on Feb. 29, Rare Disease Day, chapters from notable scientific books and clinical review articles covering rare disorders will be available free-of-charge from Elsevier. The offer runs through April 30, and aims to supports work by researchers and clinicians into a better understanding of and treatments for rare diseases, as well…
You literally can’t miss it in the news these days — millions (if not billions) of people all over the world are talking about the increasing spread of “the new (novel) Coronavirus.” According to the Center for Disease Control (CDC), the earliest cases of COVID-19 began in the city of…
Inhaling secretions produced by lung stem cells could be therapeutically beneficial for those with idiopathic pulmonary fibrosis (IPF), a preclinical study has suggested. The study, “Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis,” was published in the journal Nature…
ART-123 (thrombomodulin alfa) failed to prolong the survival of patients with idiopathic pulmonary fibrosis (IPF) who have acute exacerbations, a study found. The study, “Thrombomodulin alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Randomized, Double-blind, Placebo-controlled Trial,” was published in the American…
A decline in back muscle mass is linked to poor clinical outcomes in patients with idiopathic pulmonary fibrosis (IPF), and can be used as an independent predictor of disease prognosis, a study found. The study, “Early decrease…
